Program
Anti-CDH17/Exatecan Antibody-drug Conjugate ARR-217
Also written as “MRG007” and “MRG007 and Bevacizumab”.
Its studies are mostly in Colorectal Neoplasms, led by ArriVent BioPharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ArriVent BioPharma | 11 open or running | phase 1since Jun 26, 2025 | Jun 26, 2025 | Mar 2028phase 1 · NCT07066657 |
Also a collaborator on its studies: Lepu Biopharma.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 26, 2025First study: phase 1 study in Colorectal NeoplasmsFirst studyNCT07066657 · 572 planned · United States, China
Ahead
- Mar 2028Primary completion: phase 1 study in Colorectal NeoplasmsNCT07066657
TargetBeta
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) cadherin-17 (CDH17) site-specifically ”NCIt, by rule
Other programs on CDH17
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-CDH17 Antibody-drug Conjugate HS-20110 | Hansoh Pharmaceutical Group | phase 2 | 2 |
| Anti-CDH17/MF-6 Antibody-drug Conjugate 7MW4911rule | Mabwell (Shanghai) Bioscience | phase 2 | 2 |
| AMT-676rule | multitude-therapeutics-inc | phase 2 | 2 |
| Anti-CDH17/Topoisomerase I Inhibitor Antibody-drug Conjugate DB-1324rule | dualitybio-inc | phase 2 | 1 |
| LM-350 | Sino Biopharmaceutical | phase 2 | 1 |
| Anti-CDH17 Antibody-drug Conjugate YL217rule | MediLink Therapeutics (Suzhou) | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07066657Colorectal Neoplasms · United States, China | 1 | Recruiting | Mar 2028 | 572 |
How it is read
Names in the registry
- “MRG007”, 1 entry
- “MRG007 and Bevacizumab”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.